MTEC AWARDS DENGUE HUMAN INFECTION MODEL
PROTOTYPE DEVELOPMENT PROJECT

Charleston, SC – In partnership with the U.S. Army Medical Research and Materiel Command (USAMRMC), the Medical Technology Enterprise Consortium (MTEC) is pleased to announce that the University of Maryland, Baltimore (UMB) has been awarded funds to research and refine a dengue human infection model (DHIM) regulated by the Food and Drug Administration (FDA).

MTEC awarded project ceiling in the amount of $2,002,908 to UMB’s Center for Vaccine Development. UMB’s FDA Phase 1 research will focus on developing a DHIM that can safely and reproducibly create uncomplicated dengue infections in human volunteers for application in human vaccine testing, human immune response evaluation, and human drug trials.

MTEC and USAMRMC hope that the model developed by UMB can be used and shared within the scientific community and the Department of Defense for the efficient and expedient evaluation of leading drugs and vaccine constructs against dengue fever. The results of this research will also provide insight into strategies to simulate exposure of individuals to wild-type dengue infection.

Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board congratulated the UMB Center for Vaccine Development on this award. “UMB’s efforts to develop a reliable and safe DHIM will help to improve the military’s ability to prevent and treat dengue fever among our warfighters. MTEC is pleased to be a part of their efforts to protect our servicemen and women,” Martinez stated.

MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Materiel Command. To find out more about MTEC, visit www.mtec-sc.org.